Oct 2026· Chemical Biology and Drug Design· Vol 108· 0 citations· 86 references
Medicine
TL;DR
A critically underexplored dimension, multi‐target drug discovery, is systematically examined, focusing on the design of dual‐pharmacophore inhibitors that simultaneously engage NDH‐2 and cytochrome bd oxidase, thereby raising the genetic barrier to resistance.
Abstract
Latent tuberculosis (TB), caused by dormant, non‐replicating Mycobacterium tuberculosis (Mtb), afflicts an estimated 1.7 billion individuals globally and remains a principal barrier to TB eradication. Dormant bacilli are phenotypically tolerant to conventional antibiotics and survive through continued dependence on oxidative phosphorylation (OXPHOS) and the electron transport chain (ETC), making bioenergetic enzymes, including the F1Fo‐ATP synthase, cytochrome bcc:aa3 supercomplex, Type II NADH dehydrogenase (NDH‐2) and cytochrome bd oxidase, compelling drug targets. This review proposes and rigorously analyses a synergistic, multi‐scale computational workflow as a uniquely powerful paradigm for discovering anti‐persister agents. The workflow cascades across four integrated stages: (1) dormancy‐specific Quantitative Structure–Activity Relationship (QSAR) modelling using hypoxic assay data, with predictive models achieving R2 values of 0.83–0.98; (2) rational scaffold design and pharmacophore‐guided hit expansion against structurally validated bioenergetic targets, incorporating bioisosteric replacement and fragment merging strategies; (3) structure‐based molecular docking exploiting high‐resolution cryo‐EM structures (resolution ≤ 2.67 Å), with clinically validated inhibitors such as Bedaquiline (BDQ) yielding docking scores of −12.3 to −15.8 kcal/mol; and (4) advanced Molecular Dynamics (MD) simulation under physiologically relevant conditions, including Constant pH MD (CpHMD) at phagosomal pH 4.5 and all‐atom mycomembrane models. A critically underexplored dimension, multi‐target drug discovery, is systematically examined, focusing on the design of dual‐pharmacophore inhibitors that simultaneously engage NDH‐2 and cytochrome bd oxidase, thereby raising the genetic barrier to resistance. By framing discovery as a logical progression from statistical correlation (QSAR) through structural hypotheses (scaffold design and docking) to dynamic atomistic validation (MD), this review provides a rigorous, quantitatively grounded computational roadmap for the next generation of anti‐persister therapeutics.
It is concluded that the top-down pipeline-spanning network pharmacology to ML, docking, and MD-integrated with bottom-up feedback constitutes a closed-loop paradigm that accelerates lead identification while addressing emergent drug resistance.
Ya-Jing Zhao, Chao Wang, Wen-Jing Shang et al.· Frontiers in Pharmacology· 0 citations
Mycobacterium tuberculosis (Mtb) caused disease Tuberculosis (TB) continues to be one of the leading causes of mortality although decades of medical research has progressed. With the alarming rise in multidrug-resistant and extensively drug-resistant strains, the effectiveness of conventional therapeutic regimens is be...
N. Parvin, K. Chanda, M. Balamurali· Biochemistry and Biophysics...· 0 citations
A structure-based in silico workflow comprising virtual screening of 2,202 FDA-approved compounds, molecular docking, molecular docking, 300 ns molecular dynamics simulation, and in silico toxicity profiling provide a strong computational basis for repurposing these agents as adjunct anti-TB therapies, pending experime...
Abdallah Elssir Ahmed, Reem M. A. Ebrahim, N. M. Hajhamed et al.· Scientific Reports· 0 citations
Findings validate GlgE as a highly conserved target and identify VMP-7 as a promising lead candidate for further preclinical development of novel anti-TB therapeutics.
Pratik Mahajan, Sushama Jadhav, A. Singh et al.· Frontiers in Microbiology· 0 citations
The identification of PabB protein as an essential metabolic drug target, coupled with screening of FDA-approved drugs as inhibitors, provides a promising framework for anti tubercular drug discovery.
Antimicrobial resistance (AMR) remains a critical global health challenge, with the RND‐type MexAB–OprM efflux system of
Pseudomonas aeruginosa
playing a central role in intrinsic multidrug resistance (MDR) through the active extrusion of diverse antibiotics. In this study, we screened natural product libraries t...
Adarsha Sarmah, Anto Antony Selvaraj, N. Rameshkumar et al.· ChemistrySelect· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.